The tolerogenic theory posits that extracorporeal photopheresis (ECP) efficacy may be ascribed to the induction of immunologic tolerance. This tolerance may be achieved through one or more factors that occur following the reinfusion of cells induced to undergo apoptosis. The first factor is a modification in the antigen-presenting cell (APC) population. In the absence of danger signals, uptake of apoptotic cells can prevent the maturation of dendritic cells and inhibit their antigen presenting capacity.5,16 Induction of tolerance may also be mediated by increased production of TGF-beta and IL-10. 8,10,14 Conversely, a decrease in pro-inflammatory cytokines such as TNF and IL-12 has also been shown after ECP. 1,5 Another possible factor is the induction of regulatory T-cells, or Tregs. Regulatory T-cells have been shown to contribute to tolerance via several actions, including controlling APC maturation and effector cell responses. 2,9,15,17
Specially designed for medical professionals to use in their practice.
See top Opinion Leaders address FAQs about THERAKOS™ Photopheresis
Methoxsalen Sterile Solution is indicated for extracorporeal administration with the THERAKOS™ UVAR XTS® or THERAKOS™ CELLEX® Photopheresis System in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) that is unresponsive to other forms of treatment.
Methoxsalen is not appropriate for patients who have had a reaction to psoralen compounds, patients who have had a light sensitive disease, or patients with an absence of one or both lenses of the eye.
THERAKOS™ Photopheresis is not appropriate for patients who cannot tolerate blood volume changes or patients with blood clotting disorders. See Important Safety Information for additional details.